Kymab Ltd

Kymab Ltd

Monoclonal antibody drug discovery focus

Telephone: +44 (0)1223 833 301
Address: Meditrina (B260), Babraham Research Campus, Babraham
Postcode: CB22 3AT
Country: United Kingdom
Website: http://www.kymab.com
Membership type:Corporate 51+ (£1,000+VAT pa)

Using world-class embryonic stem cell and recombineering technologies, Kymab has developed a proprietary human antibody discovery platform, Kymouse™. The platform is designed to have a superior repertoire of B-cell mediated immune responses to current in vivo systems. We are using the Kymouse™ platform to discover and develop potent and selective therapies.

As a “platform to product” biopharmaceutical company, our strategy is to use our proprietary Kymouse ™ for the in-house development of a product portfolio and to partner with others to maximise its application in the development of novel therapeutics.

Kymab receives $9m grant from Bill & Melinda Gates Foundation

Kymab receives $9m grant from the Bill & Melinda Gates Foundation

Kymab Group Limited, a leading monoclonal antibody biopharmaceutical group, announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.

9 January 2017Read in full

Woman with pipette - Kymab

Antibody shows dramatic post-transplant benefit in animal model

Kymab's new therapeutic antibody for autoimmune diseases, KY1005, shows potential for improvement in post-transplant survival in an animal model of Graft-versus-Host Disease.

6 December 2016Read in full

Kymab secures US$100 million Series C funding

Kymab secures US$100 million Series C funding

Kymab Group Limited, a leading monoclonal antibody biopharmaceutical group, announced that it has successfully secured a US$100 million (£81 million) Series C financing.

24 November 2016Read in full

Kymab signs bispecific antibody agreement with EpimAb

Kymab signs bispecific antibody agreement with EpimAb

Kymab Limited, a leading human monoclonal antibody biopharmaceutical company based at the Babraham Research Campus, and EpimAb Biotherapeutics, Inc., an emerging Chinese biopharmaceutical company specialising in bispecific antibodies, today announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets.

11 October 2016Read in full

Kymab secures US $40 million investment

Kymab secures US $40 million investment from two of the largest foundations in the world to advance clinical development of antibody therapeutics. Series B Financing includes the Wellcome Trust and the Bill & Melinda Gates Foundation.

16 May 2014Read in full